Overview

Preventive Approach Using Venlafaxine

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

Peripheral and Motor neuropathy represent a main obstacle for a better quality of life for cancer patients, Venlafaxine is introduced in a new dosing regimen for treating of oxaliplatin and taxanes induced peripheral neuropathy in cancer patients.

Phase:

Phase 4

Details

Lead Sponsor:

Mit Ghamr Oncology Center

Treatments:

Gabapentin
Venlafaxine Hydrochloride